Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc. is listed today as Rapid Micro Biosystems, Inc.: market value, financials and filings are on its company page.
Funding rounds
7 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2018 | $60 M | No. 7 | $50 to $250 million | equity | SEC | |
| Apr 2015 | $19 M | No. 6 | $10 to $50 million | equity | SEC | |
| Apr 2014 | $6 M | No. 5 | $2 to $10 million | equity | SEC | |
| Jun 2013 | $22 M | No. 4 | $10 to $50 million | equity | SEC | |
| Nov 2012 | $1 M | No. 3 | Under $2 million | debt, options | SEC | |
| Apr 2012 | $3 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Jul 2009 | $19 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Rapid Micro Biosystems Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2019).
SEC Form D · Aug 2019
The industry group it chose in its notices: Other Health Care.
SEC Form D · Aug 2019
That is all the official record says: Rapid Micro Biosystems Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Rapid Micro Biosystems Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Bain Capital Life Sciences Investors, LLC | Fund or asset manager | not stated | not stated | Held Series B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Bain Capital Life Sciences Partners, LP | Fund or asset manager | not stated | not stated | Held Series B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BCIP Life Sciences Associates, LP | Fund or asset manager | not stated | not stated | Held Series B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Gurinder Grewal | Person | not stated | not stated | Held Series D1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longitude Capital Partners II, LLC | Fund or asset manager | not stated | not stated | Held Series A1, B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longitude Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series A1, B1 and C1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 18 investors.
Largest shareholders today
Institutions holding Rapid Micro Biosystems, Inc. shares, as of Sep 30, 2026.
- Bain Capital Life Sciences Investors, LLC$9 M20.14%
- Armistice Capital, LLC$2 M4.82%
- ABG-WTT Global Life Science Capital Partners GP Ltd$2 M4.41%
- Vanguard Capital Management LLC$1 M2.28%
- Khazanah Nasional Berhad$1 M1.35%
- Geode Capital Management, LLC$0 M0.59%
- Renaissance Technologies LLC$0 M0.57%
- BlackRock, Inc.$0 M0.47%
- Vanguard Fiduciary Trust Co$0 M0.44%
- Millennium Management LLC$0 M0.44%
- Citadel Advisors LLC$0 M0.44%
- Corient Private Wealth LP$0 M0.41%
- State Street Corp$0 M0.22%
- Gsa Capital Partners LLP$0 M0.19%
- XTX Topco Ltd$0 M0.16%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Robert Spignesi | Executive officer | Aug 2019 |
| Sean Wirtjes | Executive officer | Aug 2019 |
| Richard Kollender | Executive officer | May 2018 |
| Michael J. Mullen | Executive officer | Apr 2014 |
| Stephen H. Delity | Executive officer | Apr 2014 |
| Michael J Mullen | Executive officer | Jul 2013 |
| Stephen H Delity | Executive officer | Jul 2013 |
| Stephen M. Delity | Executive officer | Nov 2012 |
| Donald Straus | Executive officer | Jul 2009 |
| Michael Ellis | Executive officer | Jul 2009 |
| Stephen Delity | Executive officer | Jul 2009 |
| Bruce Cohen | Director | Aug 2019 |
| Christopher Cashman | Director | Aug 2019 |
| David Hirsch | Director | Aug 2019 |
| Jeffrey Schwartz | Director | Aug 2019 |
| Natale Ricciardi | Director | Aug 2019 |
| Richard Kollender | Director | Aug 2019 |
| Robert Spignesi | Director | Aug 2019 |
| Bruce M. Cohen | Director | May 2018 |
| Christopher M. Cashman | Director | May 2018 |
| David M. Hirsch | Director | May 2018 |
| Jeffrey M. Schwartz | Director | May 2018 |
| Luc Sherrill Marengere | Director | May 2018 |
| Natale M. Ricciardi | Director | May 2018 |
| P. Sherrill Neff | Director | May 2018 |
| Fred M. Cohen | Director | May 2015 |
| Richard S. Kollender | Director | May 2015 |
| Tom S. Monath | Director | May 2015 |
| Stephen H. Delity | Director | Apr 2014 |
| Christopher M Cashman | Director | Jul 2013 |
| David J Hirsch | Director | Jul 2013 |
| Donald J Straus | Director | Jul 2013 |
| Mark G Cipriano | Director | Jul 2013 |
| Mark J Braganza | Director | Jul 2013 |
| Richard J Kollender | Director | Jul 2013 |
| Stephen H Delity | Director | Jul 2013 |
| Thomas P Monath | Director | Jul 2013 |
| Don S. Straus | Director | Nov 2012 |
| Mark G. Cipriano | Director | Nov 2012 |
| Stephen M. Delity | Director | Nov 2012 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.